Literature DB >> 17142325

FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells.

Francesca Bianchi1, Alessandra Magnifico, Clelia Olgiati, Nicola Zanesi, Yuri Pekarsky, Elda Tagliabue, Carlo Maria Croce, Sylvie Ménard, Manuela Campiglio.   

Abstract

The tumor suppressor gene FHIT is inactivated by genetic and epigenetic changes in the majority of common human cancers. The human Fhit protein undergoes phosphorylation on tyrosine residue 114 by Src and related kinases both in vitro and in vivo. Src is a key cytoplasmic tyrosine kinase downstream to several growth factor receptors, including those of the EGF receptor family, which are overexpressed and activated in about one-third of human breast and ovarian carcinomas. However, the biological significance of Fhit phosphorylation by Src has remained elusive. In the present study, we demonstrate that FHIT acts as a checkpoint in cell proliferation mediated by activated tyrosine kinase receptors that recruit Src. Activation of EGF receptor family members induced Fhit phosphorylation by Src and the subsequent proteasome degradation of the phosphorylated Fhit protein. Indeed, the use of the Fhit mutant Y114F, which carries a phenylalanine instead of a tyrosine at position 114, unable to be phosphorylated on tyrosine 114 by Src, prevents Fhit degradation. Moreover, Fhit protein reduction is transient and occurs in a specific temporal window. During the signaling pathway of activated tyrosine kinase receptors, the phosphorylation of Fhit induces its degradation and the subsequent reduction in Fhit protein levels allows the transmission of the mitogenic signal; immediately thereafter, Fhit protein levels are restored. Such a scenario would suggest a key role for Fhit in the balance of proliferation/survival/apoptosis signals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142325      PMCID: PMC1679754          DOI: 10.1073/pnas.0605821103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Role of p53 in HER2-induced proliferation or apoptosis.

Authors:  P Casalini; L Botta; S Menard
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

Review 2.  Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.

Authors:  H Ishii; K R Dumon; A Vecchione; L Y Fong; R Baffa; K Huebner; C M Croce
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

3.  FHIT gene therapy prevents tumor development in Fhit-deficient mice.

Authors:  K R Dumon; H Ishii; L Y Fong; N Zanesi; V Fidanza; R Mancini; A Vecchione; R Baffa; F Trapasso; M J During; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 4.  FHIT: from gene discovery to cancer treatment and prevention.

Authors:  Yuri Pekarsky; Nicola Zanesi; Alexey Palamarchuk; Kay Huebner; Carlo M Croce
Journal:  Lancet Oncol       Date:  2002-12       Impact factor: 41.316

5.  Phosphorylation of the human Fhit tumor suppressor on tyrosine 114 in Escherichia coli and unexpected steady state kinetics of the phosphorylated forms.

Authors:  Preston N Garrison; Angela K Robinson; Yuri Pekarsky; Carlo M Croce; Larry D Barnes
Journal:  Biochemistry       Date:  2005-04-26       Impact factor: 3.162

6.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival.

Authors:  A P Belsches-Jablonski; J S Biscardi; D R Peavy; D A Tice; D A Romney; S J Parsons
Journal:  Oncogene       Date:  2001-03-22       Impact factor: 9.867

7.  The tumor spectrum in FHIT-deficient mice.

Authors:  N Zanesi; V Fidanza; L Y Fong; R Mancini; T Druck; M Valtieri; T Rüdiger; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

8.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

9.  Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding.

Authors:  Francesco Trapasso; Agnieszka Krakowiak; Rossano Cesari; Jeffrey Arkles; Sai Yendamuri; Hideshi Ishii; Andrea Vecchione; Tamotsu Kuroki; Pawel Bieganowski; Helen C Pace; Kay Huebner; Carlo M Croce; Charles Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

Review 10.  Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.

Authors:  J S Biscardi; R C Ishizawar; C M Silva; S J Parsons
Journal:  Breast Cancer Res       Date:  2000-03-07       Impact factor: 6.466

View more
  14 in total

1.  Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.

Authors:  Yi Xie; Takeo Nakanishi; Karthika Natarajan; Lowell Safren; Anne W Hamburger; Arif Hussain; Douglas D Ross
Journal:  Biochim Biophys Acta       Date:  2015-01-21

Review 2.  Common fragile site tumor suppressor genes and corresponding mouse models of cancer.

Authors:  Alessandra Drusco; Yuri Pekarsky; Stefan Costinean; Anna Antenucci; Laura Conti; Stefano Volinia; Rami I Aqeilan; Kay Huebner; Nicola Zanesi
Journal:  J Biomed Biotechnol       Date:  2010-12-29

Review 3.  Fhit tumor suppressor: guardian of the preneoplastic genome.

Authors:  Flavia Pichiorri; Tiziana Palumbo; Sung-Suk Suh; Hiroshi Okamura; Francesco Trapasso; Hideshi Ishii; Kay Huebner; Carlo M Croce
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

4.  The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.

Authors:  Jörg Weiske; Kai Frederik Albring; Otmar Huber
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-10       Impact factor: 11.205

5.  Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions.

Authors:  Flavia Pichiorri; Hiroshi Okumura; Tatsuya Nakamura; Preston N Garrison; Pierluigi Gasparini; Sung-Suk Suh; Teresa Druck; Kelly A McCorkell; Larry D Barnes; Carlo M Croce; Kay Huebner
Journal:  J Biol Chem       Date:  2008-11-12       Impact factor: 5.157

6.  Mining to find the lipid interaction networks involved in Ovarian Cancers.

Authors:  Rajaraman Kanagasabai; Kothandaraman Narasimhan; Hong-Sang Low; Wee Tiong Ang; Aaron Z Fernandis; Markus R Wenk; Mahesh A Choolani; Christopher J O Baker
Journal:  Summit Transl Bioinform       Date:  2009-03-01

7.  Tyrosine phosphorylation of cofilin at Y68 by v-Src leads to its degradation through ubiquitin-proteasome pathway.

Authors:  Y Yoo; H J Ho; C Wang; J-L Guan
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

8.  Activation state-dependent interaction between Gαq subunits and the Fhit tumor suppressor.

Authors:  Hao Zuo; Grace P W Chan; Jing Zhu; Wendy W S Yeung; Anthony S L Chan; Hermann Ammer; Yung H Wong
Journal:  Cell Commun Signal       Date:  2013-08-15       Impact factor: 5.712

9.  FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

Authors:  Svenja Dannewitz Prosseda; Xuefei Tian; Kazuya Kuramoto; Mario Boehm; Deepti Sudheendra; Kazuya Miyagawa; Fan Zhang; David Solow-Cordero; Joshua C Saldivar; Eric D Austin; James E Loyd; Lisa Wheeler; Adam Andruska; Michele Donato; Lingli Wang; Kay Huebner; Ross J Metzger; Purvesh Khatri; Edda Spiekerkoetter
Journal:  Am J Respir Crit Care Med       Date:  2019-01-01       Impact factor: 30.528

Review 10.  Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease.

Authors:  Kallirroi Voudouri; Aikaterini Berdiaki; Maria Tzardi; George N Tzanakakis; Dragana Nikitovic
Journal:  Anal Cell Pathol (Amst)       Date:  2015-07-15       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.